Abstract
Recent advances in radiotherapy technology now enable us to deliver a booster dose of radiation to small target fractions in a malignant tumor. To fully exploit this technology in cancer therapy, it is necessary to clarify the location and dynamics of radioresistant cells in heterogeneous tumor microenvironments. Tumor cells in which the transcriptional activity of hypoxia-inducible factor 1 (HIF-1) is extremely high are recognized as potential targets, because HIF-1 has been strongly associated with tumor angiogenesis, invasion, metastasis, and poor prognosis after radiation therapy. In this review, we focus on recent advances in our understanding of [1] the molecular mechanism underlying the regulation of HIF-1s transcriptional activity, [2] the influence of radiation-induced alterations of the tumor microenvironment on intratumor HIF-1 activity, [3] HIF-1-mediated tumor radioresistance, and [4] an optimal treatment protocol for the combination of a HIF-1 inhibitor and radiation therapy.
Keywords: Radiation Therapy, tumor hypoxia, tumor microenvironment, hypoxia-inducible factor 1 (HIF-1), reoxygenation, radioresistance, ROS, reactive oxygen species
Current Signal Transduction Therapy
Title: Hypoxia-Inducible Factor 1 in Tumor Radioresistance
Volume: 5 Issue: 3
Author(s): Hiroshi Harada and Masahiro Hiraoka
Affiliation:
Keywords: Radiation Therapy, tumor hypoxia, tumor microenvironment, hypoxia-inducible factor 1 (HIF-1), reoxygenation, radioresistance, ROS, reactive oxygen species
Abstract: Recent advances in radiotherapy technology now enable us to deliver a booster dose of radiation to small target fractions in a malignant tumor. To fully exploit this technology in cancer therapy, it is necessary to clarify the location and dynamics of radioresistant cells in heterogeneous tumor microenvironments. Tumor cells in which the transcriptional activity of hypoxia-inducible factor 1 (HIF-1) is extremely high are recognized as potential targets, because HIF-1 has been strongly associated with tumor angiogenesis, invasion, metastasis, and poor prognosis after radiation therapy. In this review, we focus on recent advances in our understanding of [1] the molecular mechanism underlying the regulation of HIF-1s transcriptional activity, [2] the influence of radiation-induced alterations of the tumor microenvironment on intratumor HIF-1 activity, [3] HIF-1-mediated tumor radioresistance, and [4] an optimal treatment protocol for the combination of a HIF-1 inhibitor and radiation therapy.
Export Options
About this article
Cite this article as:
Harada Hiroshi and Hiraoka Masahiro, Hypoxia-Inducible Factor 1 in Tumor Radioresistance, Current Signal Transduction Therapy 2010; 5 (3) . https://dx.doi.org/10.2174/157436210791920229
DOI https://dx.doi.org/10.2174/157436210791920229 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Renin-Angiotensin System Inhibitors as Therapeutic Alternatives in the Treatment of Chronic Liver Diseases
Current Medicinal Chemistry Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies
Recent Patents on Anti-Cancer Drug Discovery Cytotoxic Potential of Phenothiazines
Current Drug Targets Entropy Model for Multiplex Drug-Target Interaction Endpoints of Drug Immunotoxicity
Current Topics in Medicinal Chemistry Oxidative stress and myocarditis
Current Pharmaceutical Design Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside
Current Molecular Medicine [<sup>99m</sup>Tc(CO)<sub>3</sub>]<sup>+</sup> and [<sup>99m</sup>TcO<sub>2</sub>]<sup>+</sup> Radiolabeled Cyclic Melanotropin Peptides for Melanoma SPECT Imaging
Current Radiopharmaceuticals Importance of ABC Transporters in Drug Development
Current Pharmaceutical Design Gonadotropin-Releasing Hormone Receptor System: Modulatory Role in Aging and Neurodegeneration
CNS & Neurological Disorders - Drug Targets Recombinant Human Semenogelin-1 (Sg1) and Sg1 (1-159) form Detergent Stable Amyloid like Aggregates in vitro
Protein & Peptide Letters Inhibition of the VEGF/VEGFR Pathway Improves Survival in Advanced Kidney Cancer: A Systematic Review and Meta-Analysis
Current Drug Targets Targeting the Folate Receptor: Improving Efficacy in Inorganic Medicinal Chemistry
Current Medicinal Chemistry Anti-Angiogenic Agents and Cancer: Current Insights and Future Perspectives
Recent Patents on Anti-Cancer Drug Discovery Non-Invasive Approaches to Visualize the Endothelin Axis In Vivo Using State-of-the-Art Molecular Imaging Modalities
Mini-Reviews in Medicinal Chemistry The Cytotoxicity of Titanocene Y Against CAKI-1 Cells: An In Vitro Formulation Study
Letters in Drug Design & Discovery Role of Glioma-associated GLI1 Oncogene in Carcinogenesis and Cancertargeted Therapy
Current Cancer Drug Targets Engineered Liposomes for Drug Delivery and Biomedical Imaging
Recent Patents on Nanomedicine Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Mini-Reviews in Medicinal Chemistry Synthesis and Evaluation of Benzimidazole Derivatives as Selective COX-2 Inhibitors
Medicinal Chemistry Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94
Current Topics in Medicinal Chemistry